GlaxoSmithKline plc (GSK)
-NYSE 52.90 
0.17(0.32%) 01:26 SGT - Nasdaq Real Time Price
| Prev Close: | 52.73 |
|---|
| Open: | 52.42 |
|---|
| Bid: | 52.87 x 100 |
|---|
| Ask: | 52.88 x 1700 |
|---|
| 1y Target Est: | 48.56 |
|---|
| Beta: | 0.57 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 52.38 - 52.95 |
|---|
| 52wk Range: | 41.68 - 53.45 |
|---|
| Volume: | 783,655 |
|---|
| Avg Vol (3m): | 2,743,600 |
|---|
| Market Cap: | 128.12B |
|---|
| P/E (ttm): | 19.33 |
|---|
| EPS (ttm): | 2.74 |
|---|
| Div & Yield: | 2.20 (4.20%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Spinning RECORD: Battle Over Rosiglitazone Heats Up Two Weeks Before Crucial FDA Meetingat Forbes(Fri, 24 May)
- Glaxo Alleges Errors In Nissen's Critique Of FDA's Handling Of Avandiaat Forbes(Fri, 24 May)
- German, French Indices Vulnerable at Elevated Levelsat Motley Fool(Fri, 24 May)
- Impax Launches Generic ZomigZacks(Fri, 24 May)
- The FDA Responds To Steve Nissen's Criticism Of Upcoming Avandia Meetingat Forbes(Fri, 24 May)
- 4 Contagion Playsat Forbes(Thu, 23 May)
- Pharma Continues To Seek External R&D Funding, This Time From The Governmentat Forbes(Thu, 23 May)
- Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearingsat Forbes(Thu, 23 May)
- Glaxo, US partnering to develop new antibioticsAP(Thu, 23 May)
- Drugmakers, health groups bring poor girls vaccineAP(Fri, 10 May)
Key Statistics
| Forward P/E (1 yr): | 12.50 |
|---|
| P/S (ttm): | 3.03 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.91 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 2.9 |
|---|
| PEG Ratio (5 yr expected): | 4.17 |
|---|
Business Summary
GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide.
View More